Respiratory

In this week's podcast edition of Five Must-Know Things: novel BMS drug shows promise in IPF; Novo’s oral semaglutide compares well with injectable in weight loss; Teva looks to innovative brands to return to growth; US setback for Intercept’s NASH drug; and India’s improving environment for clinical trials.

Arrowhead has spent years in the shadows of rivals Alnylam and Ionis, but could make its mark with new ways to target cardiovascular and lung disease using RNA interference.

Bristol Myers Squibb believes LPA1 receptor inhibition is the best approach to meet the urgent need for well tolerated new pulmonary fibrosis treatment options that can improve symptoms and address the underlying cause of disease.

The IL-4/IL-3 inhibitor attained a greater reduction in exacerbations in patients with a higher level of a biomarker for type 2 inflammation according to complete pivotal data, but questions remain on the timing of regulatory filings.

In this week's podcast edition of Five Must-Know Things: strong growth in blockbuster ranks in 2022; Lilly’s donanemab slow cognitive decline; FDA approves first RSV vaccine; Pfizer anticipates revenue bolus from vaccines; and Astellas buys into ophthalmology.

Dupixent’s surprise success in COPD is welcome news, but it remains uncertain whether regulators will demand a second study readout before filing. In the meantime, Sanofi highlighted another promising late-stage candidate for the hard-to-treat disease during its Q1 results.

GSK has unveiled another targeted acquisition – of Bellus – that it hopes will bolster its presence in specialist respiratory medicine.

The US biotech has closed a financing round aimed at advancing its novel mucolytic agent for a subtype of COPD with the hopes of tapping into a market of five million patients in the US alone.

GSK and Pfizer are both likely to get FDA approval for their respiratory syncytial virus products shortly but Bavarian Nordic is progressing well with its differentiated five RSV-specific antigen jab.

Arrowhead is expecting a flurry of early-stage results from its in-house pipeline, including in lung diseases, where gene silencing platforms have so far struggled to reach, as it banks two recent milestone payments.

Sanofi and Regeneron could be poised to add another blockbuster indication to the IL-4/IL-13 inhibitor, for chronic obstructive pulmonary disease.

A busy start to the year sees the Italian firm adding to its respiratory portfolio by gaining access to the Swedish biotech’s investigational inhaled treatments.